Following a blow to the integrated contract developer and manufacturer’s client base, Cellares continues to move forward with ...

Since the launch of the Medicare GLP-1 Bridge on July 1, over 500,000 seniors have utilized the program and together saved ...

RNA-based vaccines and therapeutics may have faced a bumpy road in the U.S. recently, but a major new federal investment proves the government is still betting big on its future. | RNA-based vaccines ...

Novartis could cut around 130 jobs in Switzerland as it rethinks its biologics technical development and production footprint in Basel. | Novartis could cut about 130 jobs in Switzerland as it ...

Genentech performance marketing engagement lead Tiffany William is a self-proclaimed “newbie” in pharma marketing.  | After ...

Novartis appears to have broken the curse of the BTK inhibitor class. | Novartis appears to have broken the curse of the BTK ...

Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top ...

In a deal that will end intellectual property claims in five countries, including one before the International Trade ...

Jazz Pharmaceuticals has added a second overall survival win to Ziihera’s cap, bolstering the bispecific’s claim as the new ...

These are heady days for PharmaEssentia, a biotech that got its start 23 years ago in Taiwan, went public 10 years later and ...

Narcan maker Emergent BioSolutions is joining in on International Overdose Awareness Day by re-upping its "Ready to Rescue" ...

In its release on the CARDIO-TTRansform data, the ESC echoed AZ and Ionis’ point that Wainua suppressed circulating serum TTR ...